Completed PHASE1/PHASE2 INTERVENTIONAL 6-arm NCT01092104

A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

A Proof of Concept, Multiple Dose-Escalating Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

Sponsor: Tobira Therapeutics, Inc.

Conditions HIV-1 Infection

Interventions TBR-652 TBR-652 100 mg TBR-652 150 mg TBR-652 50 mg TBR-652 75 mg TBR-652 Matching Placebo

Updated 7 times since 2017 Last updated: Jul 3, 2013 Started: Feb 28, 2009 Primary completion: Nov 30, 2009 Completion: Nov 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01092104, this PHASE1/PHASE2 trial focuses on HIV-1 Infection and remains completed. Sponsored by Tobira Therapeutics, Inc., it has been updated 7 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tobira Therapeutics, Inc.

Data source: Tobira Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.